Study Evaluating 18F-FGln PETCT Scans for Diagnosing Various Malignant Tumors in Adults Aged 18 to 70

What this Trial Is About

Glutamine, an important nutrient for cancer cell growth, is often disrupted in cancer metabolism. Researchers are studying 18F-FGln PETCT imaging, a new method that targets this altered glutamine metabolism, to see how well it diagnoses different types of malignant tumors. This observational study aims to evaluate the diagnostic value of 18F-FGln PETCT in patients with various cancers, using tissue diagnosis as the reference standard. Participants are patients suspected of or confirmed to have malignant tumors who undergo an 18F-FGln PETCT scan. This imaging test tracks how cancer cells use glutamine, providing detailed pictures that may help in tumor detection and treatment planning. The study focuses on comparing this imaging method with current standards across a range of cancers, including brain, liver, gastric, duodenal, colorectal, and ovarian cancers. During the study, participants will have a PETCT scan where measurements like SUVMAX and tumor-to-background ratio TBR will be recorded within one day after the scan. Researchers will monitor the imaging results to assess the tracers ability to detect tumors accurately. The study involves patients aged 18 to 70 years, who follow the research protocol and provide consent. Participation includes compliance with imaging procedures and clinical evaluations related to cancer diagnosis and management.

A Prospective Study on the Diagnosis of Malignant Tumors With 18F-FGIn PET/CT